Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naive and Treatment-Experienced Subjects With Genotype 1 Chronic Hepatitis C and Human Immunodeficiency Virus Type 1 (HCV-1/HIV-1) Coinfection.

Trial Profile

Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naive and Treatment-Experienced Subjects With Genotype 1 Chronic Hepatitis C and Human Immunodeficiency Virus Type 1 (HCV-1/HIV-1) Coinfection.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs Telaprevir (Primary) ; Darunavir; Peginterferon alfa-2a; Ribavirin; Ritonavir
  • Indications Hepatitis C; HIV-1 infections
  • Focus Pharmacogenomic; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms INSIGHT
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 19 Oct 2015 Results published in the Journal of Antimicrobial Chemotherapy
    • 09 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Mar 2014 Planned End Date changed from 1 May 2014 to 1 Jun 2014 as reported by ClinicalTrials,gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top